Supplementary Table 2 from A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Autor: Dunja M.W.M te Loo, Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Frank N. van Leeuwen, Uta Flucke, H.W. Bart Schreuder, Winette T.A. van der Graaf, Eveline S.J.M. de Bont, Hanneke I. Vos, Remco R. Makkinje, Hans Gelderblom, Marieke J.H. Coenen, Melanie M. Hagleitner

Supplementary Table 2. Genetic variants associated with histologic response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7425f23f113b4c402bb1214257e49f1f
https://doi.org/10.1158/1078-0432.22454919

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment

Autor: Henk-Jan Guchelaar, Peter M. Hoogerbrugge, Melanie M. Hagleitner, Remco R. R. Makkinje, Hans Gelderblom, Winette T. A. van der Graaf, H. W. Bart Schreuder, Eveline S. J. M. de Bont, Dunja M.W.M te Loo, Marieke J H Coenen, Hanneke I. Vos, Uta Flucke, Frank N. van Leeuwen

Publikováno v: Clinical Cancer Research, 21, 15, pp. 3436-41
Clinical Cancer Research, 21(15), 3436-3441
Clinical Cancer Research, 21, 3436-41
Clinical Cancer Research, 21(15), 3436-3441. AMER ASSOC CANCER RESEARCH

Purpose: Overall survival in patients with osteosarcoma is only 60%. Poor response to chemotherapy is the dominant risk factor for poor survival. Pharmacogenetic research can offer possibilities to optimize treatment and improve outcome. We applied a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c68d2ec6c6002031db24d477e421755
https://pubmed.ncbi.nlm.nih.gov/25829401